Company Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-14 EDT			5-day change	1st Jan Change
71 ^JPY	+1.43%		-11.25%	-42.74%

05-07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
04-30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Number of employees: 37

Managers	Title	Age	Since
Haru Morita FOU	Founder	54	15-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	60	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Joseph McCracken BRD	Director/Board Member	71	18-07-31
Toshio Furuta BRD	Director/Board Member	62	18-11-30
Haru Morita FOU	Founder	54	15-12-31
Teruhisa Tajima BRD	Director/Board Member	52	15-12-31
Hideki Takeda BRD	Director/Board Member	65	15-12-31
Osamu Nureki FOU	Founder	58	15-12-31
Miyuki Shimane BRD	Director/Board Member	70	18-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	36,795,206	30,684,543 ( 83.39 %)	63 ( 0.000171 %)	83.39 %

Name	Equities	%	Valuation
Haru Morita 16.38 %	6,026,300	16.38 %	3 M ¥
Osamu Nureki 6.159 %	2,266,100	6.159 %	1 M ¥
Rheos Capital Works, Inc. (Investment Management) 3.791 %	1,395,000	3.791 %	682 587 ¥
SBI Investment Co., Ltd. 3.211 %	1,181,400	3.211 %	578 071 ¥
Yangu Kaihatsu KK 1.495 %	550,000	1.495 %	269 121 ¥
UTokyo Innovation Platform Co.,Ltd. 1.373 %	505,300	1.373 %	247 248 ¥
Fast Track Initiative, Inc. 1.287 %	473,400	1.287 %	231 639 ¥
Pegasus Tech Ventures, Inc. 1.048 %	385,600	1.048 %	188 678 ¥
Hideki Takeda 0.5253 %	193,300	0.5253 %	94 584 ¥
Chibagin Asset Management Co. Ltd. 0.4003 %	147,300	0.4003 %	72 075 ¥

Modalis Therapeutics Corp.

Y's Building, 4/F 16-5 Nihonbashikabutocho

103-0026, Tokyo

http://www.modalistx.com/jp/

address Modalis Therapeutics Corporation(4883)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-42.74%	15.32M
VERTEX PHARMACEUTICALS INCORPORATED	+4.81%	111B
REGENERON PHARMACEUTICALS, INC.	+10.93%	105B
BIONTECH SE	-12.26%	22.34B
ARGENX SE	-3.09%	21.93B
GENMAB A/S	-5.85%	18.59B
WUXI APPTEC CO., LTD.	-36.52%	18.12B
BEIGENE, LTD.	-9.77%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.48%	13.7B
SAREPTA THERAPEUTICS, INC.	+37.17%	12.45B

Bio Therapeutic Drugs